In Silico Cloning of Target Type 2 Diabetes Population for Treatments Development and Decision Support*

Author(s):  
Roberto Visentin ◽  
Michele Schiavon ◽  
Chiara Dalla Man
Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 952-P
Author(s):  
ANGELA LIBISELLER ◽  
KATHARINA M. LICHTENEGGER ◽  
JULIA KOPANZ ◽  
ANTONELLA DE CAMPO ◽  
TATJANA WIESINGER ◽  
...  

2021 ◽  
Vol 9 (1) ◽  
pp. e001557
Author(s):  
Ariana Pichardo-Lowden ◽  
Guillermo Umpierrez ◽  
Erik B Lehman ◽  
Matthew D Bolton ◽  
Christopher J DeFlitch ◽  
...  

IntroductionInnovative approaches are needed to design robust clinical decision support (CDS) to optimize hospital glycemic management. We piloted an electronic medical record (EMR), evidence-based algorithmic CDS tool in an academic center to alert clinicians in real time about gaps in care related to inpatient glucose control and insulin utilization, and to provide management recommendations.Research design and methodsThe tool was designed to identify clinical situations in need for action: (1) severe or recurrent hyperglycemia in patients with diabetes: blood glucose (BG) ≥13.88 mmol/L (250 mg/dL) at least once or BG ≥10.0 mmol/L (180 mg/dL) at least twice, respectively; (2) recurrent hyperglycemia in patients with stress hyperglycemia: BG ≥10.0 mmol/L (180 mg/dL) at least twice; (3) impending or established hypoglycemia: BG 3.9–4.4 mmol/L (70–80 mg/dL) or ≤3.9 mmol/L (70 mg/dL); and (4) inappropriate sliding scale insulin (SSI) monotherapy in recurrent hyperglycemia, or anytime in patients with type 1 diabetes. The EMR CDS was active (ON) for 6 months for all adult hospital patients and inactive (OFF) for 6 months. We prospectively identified and compared gaps in care between ON and OFF periods.ResultsWhen active, the hospital CDS tool significantly reduced events of recurrent hyperglycemia in patients with type 1 and type 2 diabetes (3342 vs 3701, OR=0.88, p=0.050) and in patients with stress hyperglycemia (288 vs 506, OR=0.60, p<0.001). Hypoglycemia or impending hypoglycemia (1548 vs 1349, OR=1.15, p=0.050) were unrelated to the CDS tool on subsequent analysis. Inappropriate use of SSI monotherapy in type 1 diabetes (10 vs 22, OR=0.36, p=0.073), inappropriate use of SSI monotherapy in type 2 diabetes (2519 vs 2748, OR=0.97, p=0.632), and in stress hyperglycemia subjects (1617 vs 1488, OR=1.30, p<0.001) were recognized.ConclusionEMR CDS was successful in reducing hyperglycemic events among hospitalized patients with dysglycemia and diabetes, and inappropriate insulin use in patients with type 1 diabetes.


2016 ◽  
Vol 25 (9) ◽  
pp. 1980-1992 ◽  
Author(s):  
Antony Stalin ◽  
Santiagu Stephen Irudayaraj ◽  
Dhandapani Ramesh Kumar ◽  
Kedike Balakrishna ◽  
Savarimuthu Ignacimuthu ◽  
...  

2014 ◽  
Vol 22 (1) ◽  
pp. 46-59 ◽  
Author(s):  
Nina Weymann ◽  
Martin Härter ◽  
Jörg Dirmaier

Sign in / Sign up

Export Citation Format

Share Document